Aprepitant for nausea, vomiting with the TC therapy of the gynecology cancer patient or the DC therapy, fosaprepitant, granisetron, protective efficacy of the dexamethasone combination therapy.
- Conditions
- uterine cancer, ovarian cancer
- Registration Number
- JPRN-UMIN000005494
- Lead Sponsor
- agasaki University (graduate school) department of Obstetrics and Gynecology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 140
Not provided
1) Patient has a serious hepatic insufficiency or renal failure 2) Patient has nausea or vomiting within 24 hours prior to chemotherapy 3) Patient has been treated with antiemetic agents within 48 hours prior to chemotherapy 4) Patient has any illness (e.g. central nervous system tumors, gastrointestinal obstruction, active peptic ulcer, brain metastasis) caused nausea or vomiting except for chemotherapy-induced nausea and vomiting 5) Patient is scheduled to receive radiation therapy to the abdomen 6) Patient has the collateral symptom that the dosage of the dexamethasone is impossible for four days 7) Patient has received Pimozide 8) Patient is judged inappropriate by the investigator as subject for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of patients with No Emesis in overall phase (0-120 hours after administration of carboplatin on day 1)
- Secondary Outcome Measures
Name Time Method